• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of pnasPNASInfo for AuthorsSubscriptionsAboutThis Article
Proc Natl Acad Sci U S A. Apr 1, 1993; 90(7): 2628–2632.
PMCID: PMC46148

Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration.

Abstract

Calcium-activated neutral proteinases (CANPs or calpains) are believed to be key enzymes in intracellular signaling cascades and potential mediators of calcium-induced neuronal degeneration. To investigate their involvement in Alzheimer disease, we identified three isoforms of muCANP (calpain I) in human postmortem brain corresponding to an 80-kDa precursor and two autolytically activated isoforms (78 and 76 kDa). As an index of changes in the in vivo activity of muCANP in Alzheimer disease, the ratio of the 76-kDa activated isoform of muCANP to its 80-kDa precursor was measured by immunoassay in selected brain regions from 22 individuals with Alzheimer disease and 18 normal controls. This muCANP activation ratio was elevated 3-fold in the prefrontal cortex from patients with Alzheimer disease but not from patients with Huntington disease. The activation ratio was also significantly elevated, but to a lesser degree, in brain regions where Alzheimer pathology is milder and has not led to overt neuronal degeneration. These findings indicate that muCANP activation is not simply a consequence of cellular degeneration but may be associated with dysfunction in many neurons before gross structural changes occur. The known influences of CANPs on cytoskeleton and membrane dynamics imply that persistent CANP activation may contribute to neurofibrillary pathology and abnormal amyloid precursor protein processing prior to causing synapse loss or cell death in the most vulnerable neuronal populations. Pharmacological modulation of the CANP system may merit consideration as a potential therapeutic strategy in Alzheimer disease.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991 Oct;30(4):572–580. [PubMed]
  • Hamos JE, DeGennaro LJ, Drachman DA. Synaptic loss in Alzheimer's disease and other dementias. Neurology. 1989 Mar;39(3):355–361. [PubMed]
  • DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990 May;27(5):457–464. [PubMed]
  • Khachaturian ZS. The role of calcium regulation in brain aging: reexamination of a hypothesis. Aging (Milano) 1989 Sep;1(1):17–34. [PubMed]
  • Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988 Oct;1(8):623–634. [PubMed]
  • Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992 Feb;12(2):376–389. [PubMed]
  • Peterson C, Gibson GE, Blass JP. Altered calcium uptake in cultured skin fibroblasts from patients with Alzheimer's disease. N Engl J Med. 1985 Apr 18;312(16):1063–1065. [PubMed]
  • Rizopoulos E, Chambers JP, Martinez AO, Wayner MJ. Kinetic properties of the [Ca2+ + Mg2+]-ATPase in Alzheimer and normal fibroblasts at low free calcium. Brain Res Bull. 1988 Nov;21(5):825–828. [PubMed]
  • Peterson C, Vanderklish P, Seubert P, Cotman C, Lynch G. Increased spectrin proteolysis in fibroblasts from aged and Alzheimer donors. Neurosci Lett. 1991 Jan 2;121(1-2):239–243. [PubMed]
  • Gibson GE, Nielsen P, Sherman KA, Blass JP. Diminished mitogen-induced calcium uptake by lymphocytes from Alzheimer patients. Biol Psychiatry. 1987 Sep;22(9):1079–1086. [PubMed]
  • Adunsky A, Baram D, Hershkowitz M, Mekori YA. Increased cytosolic free calcium in lymphocytes of Alzheimer patients. J Neuroimmunol. 1991 Aug;33(2):167–172. [PubMed]
  • Pontremoli S, Michetti M, Melloni E, Sparatore B, Salamino F, Horecker BL. Identification of the proteolytically activated form of protein kinase C in stimulated human neutrophils. Proc Natl Acad Sci U S A. 1990 May;87(10):3705–3707. [PMC free article] [PubMed]
  • Suzuki K, Ohno S. Calcium activated neutral protease--structure-function relationship and functional implications. Cell Struct Funct. 1990 Feb;15(1):1–6. [PubMed]
  • Murachi T. Intracellular regulatory system involving calpain and calpastatin. Biochem Int. 1989 Feb;18(2):263–294. [PubMed]
  • Nixon RA. Calcium-activated neutral proteinases as regulators of cellular function. Implications for Alzheimer's disease pathogenesis. Ann N Y Acad Sci. 1989;568:198–208. [PubMed]
  • Siman R, Noszek JC, Kegerise C. Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J Neurosci. 1989 May;9(5):1579–1590. [PubMed]
  • Lee KS, Frank S, Vanderklish P, Arai A, Lynch G. Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7233–7237. [PMC free article] [PubMed]
  • Caporaso GL, Gandy SE, Buxbaum JD, Ramabhadran TV, Greengard P. Protein phosphorylation regulates secretion of Alzheimer beta/A4 amyloid precursor protein. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3055–3059. [PMC free article] [PubMed]
  • Suzuki K, Imajoh S, Emori Y, Kawasaki H, Minami Y, Ohno S. Calcium-activated neutral protease and its endogenous inhibitor. Activation at the cell membrane and biological function. FEBS Lett. 1987 Aug 17;220(2):271–277. [PubMed]
  • Suzuki K, Tsuji S, Ishiura S, Kimura Y, Kubota S, Imahori K. Autolysis of calcium-activated neutral protease of chicken skeletal muscle. J Biochem. 1981 Dec;90(6):1787–1793. [PubMed]
  • Inomata M, Hayashi M, Nakamura M, Imahori K, Kawashima S. Hydrolytic and autolytic behavior of two forms of calcium-activated neutral protease (CANP). J Biochem. 1985 Aug;98(2):407–416. [PubMed]
  • Samis JA, Zboril G, Elce JS. Calpain I remains intact and intracellular during platelet activation. Immunochemical measurements with monoclonal and polyclonal antibodies. Biochem J. 1987 Sep 1;246(2):481–488. [PMC free article] [PubMed]
  • Elce JS, Sigmund L, Fox MJ. Calpain I activation is not correlated with aggregation in human platelets. Biochem J. 1989 Aug 1;261(3):1039–1042. [PMC free article] [PubMed]
  • Hayashi M, Inomata M, Saito Y, Ito H, Kawashima S. Activation of intracellular calcium-activated neutral proteinase in erythrocytes and its inhibition by exogenously added inhibitors. Biochim Biophys Acta. 1991 Sep 24;1094(3):249–256. [PubMed]
  • Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 1985 Nov;42(11):1097–1105. [PubMed]
  • Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991 Apr;41(4):479–486. [PubMed]
  • Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP., Jr Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985 Nov;44(6):559–577. [PubMed]
  • Inomata M, Hayashi M, Nakamura M, Imahori K, Kawashima S. Purification and characterization of a calcium-activated neutral protease from rabbit skeletal muscle which requires calcium ions of microM order concentration. J Biochem. 1983 Jan;93(1):291–294. [PubMed]
  • Fairbanks G, Steck TL, Wallach DF. Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochemistry. 1971 Jun 22;10(13):2606–2617. [PubMed]
  • Takeuchi KH, Saito KI, Nixon RA. Immunoassay and activity of calcium-activated neutral proteinase (mCANP): distribution in soluble and membrane-associated fractions in human and mouse brain. J Neurochem. 1992 Apr;58(4):1526–1532. [PubMed]
  • Tyler JM, Hargreaves WR, Branton D. Purification of two spectrin-binding proteins: biochemical and electron microscopic evidence for site-specific reassociation between spectrin and bands 2.1 and 4.1. Proc Natl Acad Sci U S A. 1979 Oct;76(10):5192–5196. [PMC free article] [PubMed]
  • Bennett V, Davis J, Fowler WE. Brain spectrin, a membrane-associated protein related in structure and function to erythrocyte spectrin. Nature. 1982 Sep 9;299(5879):126–131. [PubMed]
  • Pontremoli S, Sparatore B, Melloni E, Michetti M, Horecker BL. Activation by hemoglobin of the Ca2+-requiring neutral proteinase of human erythrocytes: structural requirements. Biochem Biophys Res Commun. 1984 Aug 30;123(1):331–337. [PubMed]
  • Nixon RA, Cataldo AM, Paskevich PA, Hamilton DJ, Wheelock TR, Kanaley-Andrews L. The lysosomal system in neurons. Involvement at multiple stages of Alzheimer's disease pathogenesis. Ann N Y Acad Sci. 1992 Dec 31;674:65–88. [PubMed]
  • Pontremoli S, Melloni E, Sparatore B, Salamino F, Michetti M, Sacco O, Horecker BL. Binding to erythrocyte membrane is the physiological mechanism for activation of Ca2+-dependent neutral proteinase. Biochem Biophys Res Commun. 1985 Apr 16;128(1):331–338. [PubMed]
  • Schlaepfer WW. Neurofilaments: structure, metabolism and implications in disease. J Neuropathol Exp Neurol. 1987 Mar;46(2):117–129. [PubMed]
  • O'Brien RA, Ostberg AJ, Vrbova G. Protease inhibitors reduce the loss of nerve terminals induced by activity and calcium in developing rat soleus muscles in vitro. Neuroscience. 1984 Jun;12(2):637–646. [PubMed]
  • Perlmutter LS, Siman R, Gall C, Seubert P, Baudry M, Lynch G. The ultrastructural localization of calcium-activated protease "calpain" in rat brain. Synapse. 1988;2(1):79–88. [PubMed]
  • Fukuda T, Adachi E, Kawashima S, Yoshiya I, Hashimoto PH. Immunohistochemical distribution of calcium-activated neutral proteinases and endogenous CANP inhibitor in the rabbit hippocampus. J Comp Neurol. 1990 Dec 1;302(1):100–109. [PubMed]
  • Cataldo AM, Paskevich PA, Kominami E, Nixon RA. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):10998–11002. [PMC free article] [PubMed]
  • Saitoh T, Masliah E, Jin LW, Cole GM, Wieloch T, Shapiro IP. Protein kinases and phosphorylation in neurologic disorders and cell death. Lab Invest. 1991 May;64(5):596–616. [PubMed]
  • Masliah E, Iimoto DS, Saitoh T, Hansen LA, Terry RD. Increased immunoreactivity of brain spectrin in Alzheimer disease: a marker for synapse loss? Brain Res. 1990 Oct 29;531(1-2):36–44. [PubMed]
  • Mantle D, Perry EK. Comparison of Ca(2+)-activated proteinase enzyme and endogenous inhibitor activity in brain tissue from normal and Alzheimer's disease cases. J Neurol Sci. 1991 Apr;102(2):220–224. [PubMed]
  • Nilsson E, Alafuzoff I, Blennow K, Blomgren K, Hall CM, Janson I, Karlsson I, Wallin A, Gottfries CG, Karlsson JO. Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue. Neurobiol Aging. 1990 Jul-Aug;11(4):425–431. [PubMed]
  • Saido TC, Mizuno K, Suzuki K. Proteolysis of protein kinase C by calpain: effect of acidic phospholipids. Biomed Biochim Acta. 1991;50(4-6):485–489. [PubMed]
  • Chakrabarti AK, Dasgupta S, Banik NL, Hogan EL. Regulation of the calcium-activated neutral proteinase (CANP) of bovine brain by myelin lipids. Biochim Biophys Acta. 1990 Apr 19;1038(2):195–198. [PubMed]
  • Landfield PW, Campbell LW, Hao SY, Kerr DS. Aging-related increases in voltage-sensitive, inactivating calcium currents in rat hippocampus. Implications for mechanisms of brain aging and Alzheimer's disease. Ann N Y Acad Sci. 1989;568:95–105. [PubMed]
  • Hu RJ, Bennett V. In vitro proteolysis of brain spectrin by calpain I inhibits association of spectrin with ankyrin-independent membrane binding site(s). J Biol Chem. 1991 Sep 25;266(27):18200–18205. [PubMed]
  • Schwarz-Ben Meir N, Glaser T, Kosower NS. Band 3 protein degradation by calpain is enhanced in erythrocytes of old people. Biochem J. 1991 Apr 1;275(Pt 1):47–52. [PMC free article] [PubMed]
  • James P, Vorherr T, Krebs J, Morelli A, Castello G, McCormick DJ, Penniston JT, De Flora A, Carafoli E. Modulation of erythrocyte Ca2+-ATPase by selective calpain cleavage of the calmodulin-binding domain. J Biol Chem. 1989 May 15;264(14):8289–8296. [PubMed]
  • Glaser T, Kosower NS. Calpain-calpastatin and fusion. Fusibility of erythrocytes is determined by a protease-protease inhibitor [calpain-calpastatin] balance. FEBS Lett. 1986 Sep 29;206(1):115–120. [PubMed]
  • Xie XY, Barrett JN. Membrane resealing in cultured rat septal neurons after neurite transection: evidence for enhancement by Ca(2+)-triggered protease activity and cytoskeletal disassembly. J Neurosci. 1991 Oct;11(10):3257–3267. [PubMed]
  • Pontremoli S, Melloni E, Damiani G, Salamino F, Sparatore B, Michetti M, Horecker BL. Effects of a monoclonal anti-calpain antibody on responses of stimulated human neutrophils. Evidence for a role for proteolytically modified protein kinase C. J Biol Chem. 1988 Feb 5;263(4):1915–1919. [PubMed]
  • Van Nostrand WE, Wagner SL, Shankle WR, Farrow JS, Dick M, Rozemuller JM, Kuiper MA, Wolters EC, Zimmerman J, Cotman CW, et al. Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2551–2555. [PMC free article] [PubMed]
  • del Cerro S, Larson J, Oliver MW, Lynch G. Development of hippocampal long-term potentiation is reduced by recently introduced calpain inhibitors. Brain Res. 1990 Oct 15;530(1):91–95. [PubMed]
  • Pettegrew JW. Molecular insights into Alzheimer's disease. Ann N Y Acad Sci. 1989;568:5–28. [PubMed]
  • Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML, Neve RL. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 1989 Jul 28;245(4916):417–420. [PubMed]
  • Wurtman RJ. Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. Trends Neurosci. 1992 Apr;15(4):117–122. [PubMed]
  • Farooqui AA, Horrocks LA. Excitatory amino acid receptors, neural membrane phospholipid metabolism and neurological disorders. Brain Res Brain Res Rev. 1991 May-Aug;16(2):171–191. [PubMed]
  • Klunk WE, McClure RJ, Pettegrew JW. Possible roles of L-phosphoserine in the pathogenesis of Alzheimer's disease. Mol Chem Neuropathol. 1991 Aug;15(1):51–73. [PubMed]
  • Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 1991 Nov 1;563(1-2):311–314. [PubMed]
  • Minami N, Tani E, Maeda Y, Yamaura I, Fukami M. Effects of inhibitors of protein kinase C and calpain in experimental delayed cerebral vasospasm. J Neurosurg. 1992 Jan;76(1):111–118. [PubMed]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...